Difference between revisions of "Upper tract urothelial carcinoma"
Jump to navigation
Jump to search
| Line 2: | Line 2: | ||
==General== | ==General== | ||
*Low-grade | *Low-grade upper tract urothelial carcinoma may be managed via endoscopic approaches.<ref name=pmid17437430>{{cite journal |authors=Argyropoulos AN, Tolley DA |title=Upper urinary tract transitional cell carcinoma: current treatment overview of minimally invasive approaches |journal=BJU Int |volume=99 |issue=5 |pages=982–7 |date=May 2007 |pmid=17437430 |doi=10.1111/j.1464-410X.2007.06870.x |url=}}</ref> | ||
*May be associated with [[Lynch syndrome]] - [[MMR testing]] typically indicated. | *May be associated with [[Lynch syndrome]] - [[MMR testing]] typically indicated. | ||
Revision as of 18:33, 3 September 2024
Upper tract urothelial carcinoma, is a urothelial carcinoma that involves the upper urinary tract (ureter, pelvis, kidney). It is a considered a rare disease.[1]
General
- Low-grade upper tract urothelial carcinoma may be managed via endoscopic approaches.[2]
- May be associated with Lynch syndrome - MMR testing typically indicated.
See also
References
- ↑ Kapoor A, Allard CB, Black P, Kassouf W, Morash C, Rendon R (2013). "Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma". Can Urol Assoc J 7 (9-10): 306–11. doi:10.5489/cuaj.1578. PMC 3854466. PMID 24319507. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854466/.
- ↑ Argyropoulos AN, Tolley DA (May 2007). "Upper urinary tract transitional cell carcinoma: current treatment overview of minimally invasive approaches". BJU Int 99 (5): 982–7. doi:10.1111/j.1464-410X.2007.06870.x. PMID 17437430.